-
Something wrong with this record ?
Comparative effects of Quercetin and SRT1720 against D-galactosamine/lipopolysaccharide-induced hepatotoxicity in rats: biochemical and molecular biological investigations
MK. Kemelo, A. Horinek, NK. Canová, H. Farghali,
Language English Country Italy
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Medline Complete (EBSCOhost)
from 2007-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
PubMed
26875909
Knihovny.cz E-resources
- MeSH
- Alanine Transaminase metabolism MeSH
- Antioxidants pharmacology MeSH
- Bilirubin metabolism MeSH
- Down-Regulation drug effects MeSH
- Galactosamine adverse effects MeSH
- Heterocyclic Compounds, 4 or More Rings pharmacology MeSH
- Rats MeSH
- Real-Time Polymerase Chain Reaction MeSH
- Chemical and Drug Induced Liver Injury drug therapy MeSH
- Lipopolysaccharides adverse effects MeSH
- Random Allocation MeSH
- Rats, Wistar MeSH
- Quercetin pharmacology MeSH
- Sirtuin 1 metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
OBJECTIVE: Quercetin, a plant flavonoid with potent antioxidant action, has been shown to be ameliorative against different types of liver insults, including D-Galactosamine/Lipopolysaccharide (D-GalN/LPS). The notion that its cytoprotective effects are SIRT1 mediated is still controversial. In this work, we examined whether the synthetic allosteric SIRT1 activator, SRT1720, may similarly attenuate D-GalN/LPS-induced hepatotoxicity. MATERIALS AND METHODS: Male Wistar rats were randomly assigned into 6 groups: (1) Control, (2) Quercetin, (3) SRT1720, (4) D-GalN/LPS, (5) Quercetin + D-GalN/LPS and (6) SRT1720 + D-GalN/LPS. After twenty-four hours, the effects of these treatments were evaluated by biochemical studies, real-time PCR and Western blot. RESULTS: D-GalN/LPS treatment downregulated SIRT1 expression and markedly increased the aminotransferase, bilirubin and conjugated diene levels. Conversely, quercetin and SRT1720 pretreatments upregulated SIRT1 expression and decreased the levels of the aforementioned markers. Quercetin had more profound effect on SIRT1 expression than SRT1720. Moreover, quercetin was more efficacious than SRT1720 in combatting the cytotoxic effects of D-GalN/LPS, as evidenced by lower markers of liver injury. CONCLUSIONS: These results strongly suggest the involvement of SIRT1 in the cytoprotective effects of quercetin and SRT1720 against D-GalN/LPS-induced hepatotoxicity.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16027668
- 003
- CZ-PrNML
- 005
- 20161118104814.0
- 007
- ta
- 008
- 161005s2016 it f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)26875909
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Kemelo, M K $u Institute of Pharmacology, 1st Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic. mighty.kemelo@lf1.cuni.cz.
- 245 10
- $a Comparative effects of Quercetin and SRT1720 against D-galactosamine/lipopolysaccharide-induced hepatotoxicity in rats: biochemical and molecular biological investigations / $c MK. Kemelo, A. Horinek, NK. Canová, H. Farghali,
- 520 9_
- $a OBJECTIVE: Quercetin, a plant flavonoid with potent antioxidant action, has been shown to be ameliorative against different types of liver insults, including D-Galactosamine/Lipopolysaccharide (D-GalN/LPS). The notion that its cytoprotective effects are SIRT1 mediated is still controversial. In this work, we examined whether the synthetic allosteric SIRT1 activator, SRT1720, may similarly attenuate D-GalN/LPS-induced hepatotoxicity. MATERIALS AND METHODS: Male Wistar rats were randomly assigned into 6 groups: (1) Control, (2) Quercetin, (3) SRT1720, (4) D-GalN/LPS, (5) Quercetin + D-GalN/LPS and (6) SRT1720 + D-GalN/LPS. After twenty-four hours, the effects of these treatments were evaluated by biochemical studies, real-time PCR and Western blot. RESULTS: D-GalN/LPS treatment downregulated SIRT1 expression and markedly increased the aminotransferase, bilirubin and conjugated diene levels. Conversely, quercetin and SRT1720 pretreatments upregulated SIRT1 expression and decreased the levels of the aforementioned markers. Quercetin had more profound effect on SIRT1 expression than SRT1720. Moreover, quercetin was more efficacious than SRT1720 in combatting the cytotoxic effects of D-GalN/LPS, as evidenced by lower markers of liver injury. CONCLUSIONS: These results strongly suggest the involvement of SIRT1 in the cytoprotective effects of quercetin and SRT1720 against D-GalN/LPS-induced hepatotoxicity.
- 650 _2
- $a alanintransaminasa $x metabolismus $7 D000410
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antioxidancia $x farmakologie $7 D000975
- 650 _2
- $a bilirubin $x metabolismus $7 D001663
- 650 _2
- $a down regulace $x účinky léků $7 D015536
- 650 _2
- $a lékové postižení jater $x farmakoterapie $7 D056486
- 650 _2
- $a galaktosamin $x škodlivé účinky $7 D005688
- 650 _2
- $a heterocyklické sloučeniny tetra- a více cyklické $x farmakologie $7 D006576
- 650 _2
- $a lipopolysacharidy $x škodlivé účinky $7 D008070
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a quercetin $x farmakologie $7 D011794
- 650 _2
- $a náhodné rozdělení $7 D011897
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $7 D060888
- 650 _2
- $a sirtuin 1 $x metabolismus $7 D056564
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Horinek, A
- 700 1_
- $a Canová, N K
- 700 1_
- $a Farghali, H
- 773 0_
- $w MED00190062 $t European review for medical and pharmacological sciences $x 2284-0729 $g Roč. 20, č. 2 (2016), s. 363-71
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26875909 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161118104801 $b ABA008
- 999 __
- $a ok $b bmc $g 1165982 $s 952298
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 20 $c 2 $d 363-71 $i 2284-0729 $m European review for medical and pharmacological sciences $n Eur Rev Med Pharmacol Sci $x MED00190062
- LZP __
- $a Pubmed-20161005